Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|January 25, 2022
Daily Medication Pearl: Testosterone Enanthate (Xyosted)
Author(s)Saro Arakelians, PharmD
Xyosted is indicated for conditions associated with a deficiency or absence of endogenous testosterone.
Advertisement
Medication Pearl of the Day: Testosterone Enanthate (Xyosted)
Indication: Testosterone enanthate (Xyosted) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Insight:
- Dosing: 75 mg subcutaneously in the abdominal region once weekly. Avoid intramuscular and intravascular administration.
- Dosage forms: 50 mg/0.5 mL o 75 mg/0.5 mL o 100 mg/0.5 mL.
- Adverse events: The most commonly reported adverse reactions (>5%) were increased hematocrit, hypertension, increased prostate-specific antigen, injection site bruising, and headache.
- Mechanism of action: Endogenous androgens, including testosterone and dihydrotestosterone, are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics.
- Manufacturer: Antares Pharma
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inhaled Stem Cells for COPD: What Would Prove Lasting Benefit?
4
The Chair Was Never Just a Chair
5